Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.59
CLSN's Cash to Debt is ranked lower than
69% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CLSN: 2.59 )
Ranked among companies with meaningful Cash to Debt only.
CLSN' s Cash to Debt Range Over the Past 10 Years
Min: 0.45  Med: 31.14 Max: No Debt
Current: 2.59
Equity to Asset 0.35
CLSN's Equity to Asset is ranked lower than
80% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CLSN: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
CLSN' s Equity to Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.59 Max: 0.97
Current: 0.35
-1.05
0.97
F-Score: 3
Z-Score: -8.00
M-Score: -3.36
WACC vs ROIC
16.15%
-292.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3922.60
CLSN's Operating margin (%) is ranked lower than
87% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. CLSN: -3922.60 )
Ranked among companies with meaningful Operating margin (%) only.
CLSN' s Operating margin (%) Range Over the Past 10 Years
Min: -4943  Med: -2116.58 Max: -75.43
Current: -3922.6
-4943
-75.43
Net-margin (%) -4234.40
CLSN's Net-margin (%) is ranked lower than
88% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. CLSN: -4234.40 )
Ranked among companies with meaningful Net-margin (%) only.
CLSN' s Net-margin (%) Range Over the Past 10 Years
Min: -5098.8  Med: -1405.68 Max: -67.41
Current: -4234.4
-5098.8
-67.41
ROE (%) -90.80
CLSN's ROE (%) is ranked lower than
79% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CLSN: -90.80 )
Ranked among companies with meaningful ROE (%) only.
CLSN' s ROE (%) Range Over the Past 10 Years
Min: -6771.43  Med: -93.27 Max: 257.55
Current: -90.8
-6771.43
257.55
ROA (%) -39.76
CLSN's ROA (%) is ranked lower than
62% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CLSN: -39.76 )
Ranked among companies with meaningful ROA (%) only.
CLSN' s ROA (%) Range Over the Past 10 Years
Min: -217.17  Med: -44.46 Max: 121.96
Current: -39.76
-217.17
121.96
ROC (Joel Greenblatt) (%) -2131.89
CLSN's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CLSN: -2131.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLSN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4101.97  Med: -1418.77 Max: -115.63
Current: -2131.89
-4101.97
-115.63
EBITDA Growth (3Y)(%) -34.40
CLSN's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CLSN: -34.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLSN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.6  Med: -4.30 Max: 39.1
Current: -34.4
-57.6
39.1
EPS Growth (3Y)(%) -33.10
CLSN's EPS Growth (3Y)(%) is ranked lower than
80% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CLSN: -33.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLSN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -2.80 Max: 28.8
Current: -33.1
-48.2
28.8
» CLSN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CLSN Guru Trades in Q2 2015

Jim Simons 71,210 sh (+71.03%)
Chuck Royce 213,159 sh (unchged)
» More
Q3 2015

CLSN Guru Trades in Q3 2015

Jim Simons Sold Out
Chuck Royce 167,379 sh (-21.48%)
» More
Q4 2015

CLSN Guru Trades in Q4 2015

Jim Simons 25,648 sh (New)
Chuck Royce Sold Out
» More
Q1 2016

CLSN Guru Trades in Q1 2016

Jim Simons 27,648 sh (+7.80%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PTGEF, NAS:ICCC, NAS:OPXA, NAS:VTGN, AMEX:HEB, AMEX:CANF, NAS:SBOT, AMEX:OGEN, NAS:ABIO, NAS:CBLI, NAS:CYTX, NAS:OGXI, OTCPK:PRGB, NAS:CYAN, OTCPK:BNRPF, OTCPK:TPIV, NAS:ONCS, NAS:APTO, NAS:PULM, OTCPK:FENCF » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

Celsion Corp was founded in 1982 and is a Delaware corporation. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.

Ratios

vs
industry
vs
history
P/B 1.85
CLSN's P/B is ranked higher than
74% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CLSN: 1.85 )
Ranked among companies with meaningful P/B only.
CLSN' s P/B Range Over the Past 10 Years
Min: 1.25  Med: 2.17 Max: 167.59
Current: 1.85
1.25
167.59
P/S 55.00
CLSN's P/S is ranked lower than
76% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. CLSN: 55.00 )
Ranked among companies with meaningful P/S only.
CLSN' s P/S Range Over the Past 10 Years
Min: 2.22  Med: 20.36 Max: 585.38
Current: 55
2.22
585.38
Current Ratio 1.54
CLSN's Current Ratio is ranked lower than
82% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CLSN: 1.54 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.47 Max: 104.65
Current: 1.54
0.3
104.65
Quick Ratio 1.54
CLSN's Quick Ratio is ranked lower than
78% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CLSN: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.86 Max: 104.65
Current: 1.54
0.3
104.65
Days Sales Outstanding 19.71
CLSN's Days Sales Outstanding is ranked higher than
82% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. CLSN: 19.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLSN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.71  Med: 107.18 Max: 2190
Current: 19.71
19.71
2190

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.69
CLSN's Price/Median PS Value is ranked lower than
87% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CLSN: 2.69 )
Ranked among companies with meaningful Price/Median PS Value only.
CLSN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 4.57 Max: 4324.13
Current: 2.69
0.13
4324.13
Earnings Yield (Greenblatt) (%) -102.00
CLSN's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CLSN: -102.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLSN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 325.1  Med: 715.70 Max: 887.9
Current: -102
325.1
887.9

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.94
Beta1.92
Short Percentage of Float2.44%
52-Week Range $1.04 - 2.63
Shares Outstanding (Mil)23.44

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 0 0 0
EPS ($) -0.90 -0.52 -0.56
EPS w/o NRI ($) -0.90 -0.52 -0.56
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 

More From Other Websites
ETF’s with exposure to Celsion Corp. : July 20, 2016 Jul 20 2016
4 Speculative Biotech and Biohealth Analysts Calls for Huge Upside Jul 17 2016
Celsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver... Jul 11 2016
Celsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver... Jul 11 2016
Celsion Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 07 2016
Celsion Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 07 2016
Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus... Jun 21 2016
Celsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus... Jun 21 2016
CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jun 17 2016
CELSION CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jun 15 2016
Celsion Corporation Announces $6 Million Registered Direct Offering Jun 13 2016
CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 13 2016
Celsion Corporation Announces $6 Million Registered Direct Offering Jun 13 2016
Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 Jun 07 2016
CELSION CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 01 2016
CELSION CORP Financials May 24 2016
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting May 24 2016
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting May 24 2016
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update May 16 2016
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)